English
 
User Manual Privacy Policy Disclaimer Contact us
  Advanced SearchBrowse

Item

ITEM ACTIONSEXPORT
  Pharmacokinetics and myeloid effector cell engagement of an engineered IgA antibody against the epidermal growth factor receptor

Valerius, T., Lohse, S., Meyer, S., Jansen, M. J., Meulenbroek, L. A., Nederend, M., et al. (2015). Pharmacokinetics and myeloid effector cell engagement of an engineered IgA antibody against the epidermal growth factor receptor. Journal of Clinical Oncology, 33: abstract 3037.

Item is

Basic

show hide
Item Permalink: http://hdl.handle.net/11858/00-001M-0000-0028-79F6-C Version Permalink: http://hdl.handle.net/11858/00-001M-0000-0028-79F7-A
Genre: Meeting Abstract

Files

show Files
hide Files
:
2186361.jpg (Supplementary material), 3MB
 
File Permalink:
-
Name:
2186361.jpg
Description:
-
Visibility:
Restricted (Max Planck Institute of Colloids and Interfaces, MTKG; )
MIME-Type / Checksum:
image/jpeg
Technical Metadata:
Copyright Date:
-
Copyright Info:
-
License:
-

Locators

show

Creators

show
hide
 Creators:
Valerius, Thomas, Author
Lohse, Stefan, Author
Meyer, Saskia, Author
Jansen, Marco J.H., Author
Meulenbroek, Laura A.P., Author
Nederend, Maaike, Author
Möginger, Uwe1, Author              
Kretschmer, Anna, Author
Klausz, Katja, Author
Derer, Stefanie, Author
Sondermann, Peter, Author
Kolarich, Daniel1, Author              
Peipp, Matthias, Author
Leusen, Jeanette H.W., Author
Gramatzki, Martin, Author
Affiliations:
1Daniel Kolarich, Biomolekulare Systeme, Max Planck Institute of Colloids and Interfaces, Max Planck Society, ou_1863301              

Content

show
hide
Free keywords: online first
 Abstract: IgA antibodies play an important role in bridging adaptive and innate immunity. There is increasing evidence that FcαRI-dependent engagement of myeloid cells appears to be crucial to activate mechanisms like phagocytosis or antibody-dependent cell-mediated cytotoxicity and that myeloid cells constitute important effector cells in cancer and cancer immunotherapy. Here, we describe an Fc engineering approach to further improve the immunotherapeutic potential of IgA antibodies. Methods: Recombinant IgA antibodies against the epidermal growth factor receptor (EGFR) were produced by co-transfecting CHO-K1 cells with vectors encoding the 225 variable and Igα heavy and κ light chain constant regions, respectively. An Fc engineered IgA2 antibody was generated by mutating two N-glycosylation sites and by removing two free cysteines. The resulting antibody was compared to wild type IgA2 regarding biochemical characteristics as well as Fab and Fc-mediated effector functions. Additionally, serum half-life and in vivo efficacy in a xenogeneic FcαRI-transgenic tumor model were evaluated. Results: Rational engineering of an IgA2 antibody resulted in monomeric molecules with improved biochemical characteristics, identical Fab- and Fc- mediated effector functions, but with significantly lower levels of terminal galactose. This molecule demonstrated lower asialoglycoprotein-receptor (ASGPR) binding and subsequently improved pharmacokinetics in mice. Compared to wild type IgA, this novel molecule displayed enhanced therapeutic efficacy against A431 tumor cells in vivo, which required human FcαRI-dependent myeloid effector cell engagement. Conclusions: These results demonstrate that an Fc engineered IgA antibody against EGFR displayed improved immunotherapeutic efficacy, which may overcome limitations (stability, pharmacokinetics, in vivo efficacy) of wild type IgA antibodies. Thus, these results promote the concept of FcαRI-dependent engagement of myeloid effector cells as a promising approach for antibody-based tumor immunotherapy.

Details

show
hide
Language(s):
 Dates: 2015
 Publication Status: Published in print
 Pages: -
 Publishing info: -
 Table of Contents: -
 Rev. Type: -
 Identifiers: -
 Degree: -

Event

show
hide
Title: 2015 ASCO Annual Meeting
Place of Event: -
Start-/End Date: -

Legal Case

show

Project information

show

Source 1

show
hide
Title: Journal of Clinical Oncology
Source Genre: Journal
 Creator(s):
Affiliations:
Publ. Info: New York, NY : Grune & Stratton, supplement
Pages: - Volume / Issue: 33 Sequence Number: abstract 3037 Start / End Page: - Identifier: ISSN: 0732-183X
CoNE: https://pure.mpg.de/cone/journals/resource/954925534050